Australia markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6900-0.0400 (-1.47%)
At close: 04:00PM EDT
2.6600 -0.03 (-1.12%)
Pre-market: 08:43AM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-72,849
-72,849
-69,456
-76,247
-63,745
Depreciation & amortisation
1,404
1,404
1,427
1,753
1,978
Deferred income taxes
-
-
-
-
0
Stock-based compensation
9,301
9,301
7,182
6,424
6,161
Change in working capital
-18,233
-18,233
29,243
925
431
Accounts receivable
-424
-424
-453
413
-108
Accounts payable
-
-
5,216
1,911
1,666
Other working capital
-86,944
-86,944
-35,868
-68,341
-51,670
Other non-cash items
-3,343
-3,343
-3,698
-1,386
1,035
Net cash provided by operating activities
-85,936
-85,936
-35,356
-67,532
-51,441
Cash flows from investing activities
Investments in property, plant and equipment
-1,008
-1,008
-512
-809
-229
Acquisitions, net
-
-
-
-
-2,500
Purchases of investments
-80,509
-80,509
-130,430
-82,219
-85,578
Sales/maturities of investments
132,270
132,270
56,000
70,350
73,398
Other investing activities
-
-
-
-
-12,180
Net cash used for investing activities
50,773
50,773
-74,942
-12,678
-14,909
Cash flows from financing activities
Common stock issued
29,852
29,852
20,324
134,665
86,297
Net cash used provided by (used for) financing activities
30,647
30,647
31,814
137,236
86,746
Net change in cash
-4,491
-4,491
-78,506
57,031
20,452
Cash at beginning of period
30,776
30,776
109,282
52,251
31,799
Cash at end of period
26,285
26,285
30,776
109,282
52,251
Free cash flow
Operating cash flow
-85,936
-85,936
-35,356
-67,532
-51,441
Capital expenditure
-1,008
-1,008
-512
-809
-229
Free cash flow
-86,944
-86,944
-35,868
-68,341
-51,670